Know Cancer

or
forgot password

A Phase III Multicenter Study of Intratumoral/Interstitial Therapy With TransMID Compared to Best Standard of Care in Patients With Progressive and/or Recurrent, Non-Resectable Glioblastoma Multiforme


Phase 3
N/A
N/A
Not Enrolling
Both
Glioblastoma

Thank you

Trial Information

A Phase III Multicenter Study of Intratumoral/Interstitial Therapy With TransMID Compared to Best Standard of Care in Patients With Progressive and/or Recurrent, Non-Resectable Glioblastoma Multiforme


Study Objectives:

Primary Objective:

To evaluate the efficacy of intratumoral/interstitial therapy with TransMID compared to best
standard of care in patients with progressive and/or recurrent, non-resectable glioblastoma
multiforme.

Secondary Objectives:

To assess the safety of intratumoral/interstitial therapy with TransMID compared to best
standard of care in patients with progressive and/or recurrent, non-resectable glioblastoma
multiforme.

To evaluate possible differences in efficacy and/or safety with TransMID associated with
differing degrees of transferrin receptor expression in tumor tissue and serum
anti-diphtheria toxin antibody titer levels.

Study Design:

Multicenter, open label, randomized study comparing TransMID with a chemotherapeutic regimen
considered to be best standard of care and consisting of either nitrosureas, platinum
compounds, temozolomide, procarbazine or PCV (procarbazine, lomustine (CCNU) & vincristine).
A planned interim analysis of the primary efficacy endpoint will be conducted after
approximately 50 percent of the required events have been observed.

Inclusion Criteria


INCLUSION CRITERIA:

Patients will be included in the study if they meet all of the following criteria:

1. Male or female at least 18 years of age.

2. Histological results confirming GBM are available.

3. Progressive GBM (greater than or equal to 25 percent increase in contrast enhanced
tumor CSA compared to the nadir or smallest previous measured CSA) and/or recurrent
GBM after conventional treatment, including surgery (biopsy or debulking surgery)
and/or radiation therapy and/or chemotherapy.

4. Pre-study MRIs used to determine current progression and/or recurrence of GBM are
available to the Investigator and for independent confirmation of progression and/or
recurrence.

5. Patient is not considered a candidate for resection.

6. If female of child-bearing potential, a reliable method of contraception must be
combined with a negative pregnancy test before entering the study (female patients
must be willing to use contraception for 2 months after the last treatment with
TransMID (Trademark)). Male patients must be willing to use a barrier method of
contraception for up to 2 months after the last treatment with TransMID (Trademark)

7. Able and willing to follow instructions and comply with the protocol.

8. Provide written informed consent prior to participation in the study.

9. Karnofsky Performance Scale Score 70-100.

10. Tumor characteristics:

i) must be unifocal; and

ii) must be unilateral and supratentorial; and

iii) lesion must have a diameter (on contrast-enhanced MRI) greater than or equal to 1.0
cm and less than or equal to 4.0 cm.

EXCLUSION CRITERIA:

Patients will be excluded from the study if they meet any of the following criteria:

1. Anticipated life expectancy of less than 3 months.

2. Infratentorial or intraventricular tumors.

3. Presence of satellite tumors.

4. Chemotherapy within 30 days prior to study entry or nitrosureas or Mitomycin-C
containing therapy within 42 days prior to study entry.

5. Radiotherapy or stereotactic (gamma knife) radiosurgery within 90 days prior to study
entry.

6. Tumor surgery, tumor debulking or other neurosurgery within 30 days prior to study
entry.

7. Previous administration of TransMID (Trademark)

8. Previous enrollment in this study.

9. Regional therapy including administration of biodegradable polymer wafers containing
carmustine within 90 days prior to study entry or brachytherapy within 12 calendar
months prior to study entry.

10. Significant liver function impairment-(total bilirubin greater than 2.0 mg/dl or 34.2
mircomol/L; AST or ALT greater than 3 times the upper limit of normal).

11. Significant renal impairment (serum creatinine greater than 1.7 mg/dL or 150
micromol/L).

12. Coagulopathy (prothrombin time [PT] or activated partial thromboplastin time [APTT]
greater than 1.5 times control).

13. Thrombocytopenia (platelet count less than 100 x 10(3)/micro-L or 100 x 10(9)/L).

14. Granulocytopenia (absolute neutrophil count (ANC), less than 1 x 10(3)/micro-L or 1.0
x 10(9)/L).

15. Severe acute infection.

16. Medical condition that is considered an unacceptable anesthetic risk.

17. Evidence of a mass effect on CT or MRI with more than a 5 mm midline shift and/or
nausea, vomiting, reduced level of consciousness or clinically significant
papilledema.

18. Nursing or pregnant females. A pregnancy test will be performed on all females who
are of child-bearing potential.

19. Use of any investigational product and/or participation in another clinical research
study within the last 30 days prior to study entry.

Type of Study:

Interventional

Study Design:

Endpoint Classification: Efficacy Study, Primary Purpose: Treatment

Authority:

United States: Federal Government

Study ID:

040244

NCT ID:

NCT00088400

Start Date:

July 2004

Completion Date:

November 2005

Related Keywords:

  • Glioblastoma
  • Transferrin
  • Brain Tumor
  • Convection
  • Immunotherapy
  • Targeted Protein Toxin
  • Glioblastoma Multiforme
  • GBM
  • Brain Neoplasms
  • Glioblastoma

Name

Location

National Institute of Neurological Disorders and Stroke (NINDS)Bethesda, Maryland  20892